Tubulus co-founders decided to launch their company after a single successful experiment, driven by passion rather than a thorough market analysis. This 'healthy naivety' helped them push forward despite industry skepticism towards their antibody-drug conjugate (ADC) technology at the time, which was considered a difficult area.
Related Insights
The belief required to start a company that solves a massive, complex problem like communication isn't confidence, but a form of delusion. This mindset allows founders to persist through challenges that a more realistic person might abandon, especially when a problem seems fundamentally unsolvable.
Many founders start companies simply because they want the title, not because they are obsessed with a mission. This is a critical mistake, as only a deep, personal passion for a problem can sustain a founder through the inevitable hardships of building a startup.
Prepared's founder faced 'no's' from customers, investors, and parents. He persisted not because he was trying to build a company, but because of a stubborn, personal passion to solve a problem—believing he could make things 'slightly better' even if he ultimately failed.
A full understanding of a complex industry's challenges can be paralyzing. The founder of Buildots admitted he wouldn't have started the company if he knew how hard it would be. Naivety allows founders to tackle enormous problems that experienced operators might avoid entirely.
Lacking deep category knowledge fosters the naivety and ambition required for groundbreaking startups. This "beginner's mind" avoids preconceived limitations and allows for truly novel approaches, unlike the incrementalism that experience can sometimes breed. It is a gift, not a curse.
Unlike software startups that can "fail fast" and pivot cheaply, a single biotech clinical program costs tens of millions. This high cost of failure means the industry values experienced founders who have learned from past mistakes, a direct contrast to Silicon Valley's youth-centric culture.
Founders shouldn't be deterred by their lack of knowledge. Seeing the full scope of future challenges can be overwhelming. A degree of ignorance allows entrepreneurs to focus on immediate problems and maintain the momentum crucial for survival in the early stages.
When starting out, CDR Life had no intellectual property, data, or significant money. CEO Christian Leisner credits their success to the founding team's powerful and unwavering belief that they could succeed, which made finding a path forward a manageable challenge.
The path for biotech entrepreneurs is a long slog requiring immense conviction. Success ("liftoff") isn't just a clinical trial result, but achieving self-sustaining profitability and growth. This high bar means founders may need to persevere through years of market indifference and financing challenges.
Lacking full knowledge of a startup's immense difficulty can be an advantage for first-time founders. This naivete allows them to commit to ventures they might otherwise avoid if they knew the true challenges ahead, similar to a child fearlessly skiing down a mountain.